Mobile App Click here to download our Mobile App for iOS or Android
Not a member? Sign up for free!

Impending Signs Of Psychosis: Focus On Caregiver & Patient Engagement

Webinar | March 27, 2017 12:00 pm to 1:00 pm EST
You must be logged in to register for PsychU events. Log In

Not a member? Sign up for free!

Join us as we continue our efforts towards improving the future of mental health care through information, discussion, and collaboration.
Sign up today for instant access to all PsychU offerings. Membership is free!

Join PsychU


Virtual Forum: Impending Signs Of Psychosis: Focus On Caregiver & Patient Engagement

Location: Online Via

Description: The majority of individuals who experience psychosis in schizophrenia will eventually relapse, making an individual’s ability to identify early warning signs of psychosis and their knowledge of what to do when such signs surface important. In this virtual forum, Robert A Millet, MD, DFAPA and Kirk Morton, RN, BSN will review the importance of early identification of schizophrenia, explore the warning signs of impending psychosis in schizophrenia, and discuss considerations for healthcare providers in educating patients with schizophrenia and their caregivers. The virtual forum will conclude with time for questions from the audience.

Speakers are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc.

View Flyer (PDF)

Event Speakers

Kirk Morton, RN, BSN
Featured Speaker

Kirk Morton, RN, BSN, is the Region IV Utilization Review Specialist at Richmond Behavioral Health Authority in Richmond, VA.


Robert A. Millet, MD, DFAPA
Featured Speaker

Robert A. Millet, MD, DFAPA, is the Assistant Medical Director, Director of Clinical Research, and the Clinical Laboratory Director at Carolina Behavioral Care. Dr. Millet is the CEO and Chief Science Officer of Synapse Clinical Research, the research arm of Carolina Behavioral Care. He also serves as a scientific advisor to Synapse Analytical Labs where his research focuses on implementation of urine drug testing in behavioral health settings, improving outcomes by using urine drug testing and developing new laboratory assays for mental health medications. Dr. Millet is also the founder, CEO and Chief Science Officer of Synapse BioSciences, a biotech company involved in the invention and marketing of biomarkers to improve clinical trial outcomes by measuring long term medication adherence. Dr. Millet is on the faculty of Duke University Medical Center as a consulting clinical associate in the Department of Psychiatry and Behavioral Sciences. In 2016, Dr. Millet was appointed by the Governor to serve on North Carolina’s Board of Science, Technology and Innovation.

Robert A. Millet, MD, DFAPA received his Doctor of Medicine Degree from Louisiana State University School of Medicine in New Orleans in 1991.

Mark Tacelosky, PharmD

Mark Tacelosky, PharmD, serves as a Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc. His clinical areas of expertise include neuroscience, pain, cardiovascular disease, and metabolic disorders.

Mark attended the Philadelphia College of Pharmacy and Science in Philadelphia, Pennsylvania.

The registration for this event is now closed. For more information about our live event registration process, please read the Live Event Eligibility Requirements